Arixtra Inj.

Ingredient

Fondaparinux Sodium

Content

2.5mg/0.5ml (pre-filled syringe)

Indication

1) Prophylaxis of venous thromboembolism in patients undergoing major orthopedic surgery of the lower limb, such as hip fracture surgery, knee surgery, or hip replacement surgery
2) Prophylaxis of venous thromboembolism in patients underwent abdominal surgery, such as abdominal cancer surgery who are deemed to have a high risk of thromboembolic complications
3) Prophylaxis of venous thromboembolism in patients with limited mobility due to acute diseases such as heart failure (NYHA class Ⅲ or Ⅳ), acute respiratory disease, acute infection or inflammatory disease and medical patients who are deemed to have a high risk of venous thromboembolism
4) Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients who are not covered by emergency invasive management (Percutaneous Coronary Intervention(PCI) within 120 minutes)
5) Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are being treated with thrombolytic agents or initially not receiving other forms of reperfusion therapy